Physician
Hematology
Dr. David J. Oblon, MD
|
|
Give Review
David Oblon works in the field of Hematology. He researched medicine at Perelman School of Medicine at the University of Pennsylvania. David Oblon is a published physician. He has 27 papers published. The most current publication "Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation." David Oblon accepts Medicare payments and is registered with Medicare.gov.
Publications
- Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow-derived stem c...
- Autologous stem cell transplantation for small cell lung Cancer.
- Use of messenger RNA differential display to identify interleukin-11-responsive genes in human umbilical cord blood mononuclear cells: IL-11 upregulates the expression...
- Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
- Improved survival of patients with chronic myelogenous Leukemia undergoing allogeneic bone marrow transplantation.
- Myelodysplastic syndromes presenting in pregnancy. A report of five cases and the clinical outcome.
- HTLV-I-associated adult T-cell Leukemia/lymphoma presenting with nodular synovial masses.
- Bladder-sparing approach in the treatment of invasive bladder Cancer.
- A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associ...
- High-dose chemotherapy and autologous stem-cell transplantation for ovarian Cancer: an autologous blood and marrow transplant registry report.
- A comparison of prestorage WBC-reduced whole-blood-derived platelets and bedside-filtered whole-blood-derived platelets in autologous progenitor cell transplant.
- Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation.
- Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE).
- Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study.
- Outcome of clinical congestive heart failure induced by anthracycline chemotherapy.
- High-dose methylprednisolone therapy for Acute graft-versus-host disease associated with matched unrelated donor bone marrow transplantation.
- Acidic isoferritin inhibitory activity: a normal granulopoietic regulator within long term mouse bone marrow cultures.
- The production of colony stimulating activity by monocyte enriched fractions from murine continuous bone marrow culture adherent layers.
- Therapeutic applications of allogeneic BMT: aplastic anemia and the Leukemias.
- The reversal of myelofibrosis associated with chronic myelogenous Leukemia after allogeneic bone marrow transplantation.
- Recurrent varicella-zoster infection after acyclovir therapy in immunocompromised patients.
- Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaGlandin E2.
- Immunophenotypic characterization of an unusual T-cell Lymphoma presenting as anterior uveitis. A clinicopathologic case report.
- Intensive short-term chemotherapy for patients with Acute myelogenous leukemia: long-term follow-up.
- Etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue as re-treatment for unfavorable non-Hodgkin's Lymphoma.
- Bladder preservation and durable complete remission of small cell carcinoma of the Bladder with systemic chemotherapy and adjuvant radiation therapy.
Schools
Perelman School of Medicine University of Pennsylvania
Duke University Med Center
Shands Tchg Hospital
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
University of Florida -
Duke University Hospital -
Perelman School of Medicine at the University of Pennsylvania
Drug Facts
| NPI NUMBER | 1215072434 | |
| NPPES Provider LastName | OBLON | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 920564459 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 398.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1215072434 |
| Last Name Of The Provider | OBLON |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Divis K. Khaira, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Warren S. Paroly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nayyar Siddique, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mahnaz Shahidi-Asl, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Les Breitman, MD |